Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

28 Sep 2005 07:02

Quintessentially English PLC28 September 2005 Quintessentially English PLC ('Quintessentially English' or the 'Company') Interim Results The Company announces its interim results for the six month period to 30th June2005. There was a turnover of £Nil, and a loss after tax of £56,283. No directorsreceived any remuneration during the period. No dividend is recommended. Since the Company's successful Admission to AIM in March 2004, the Company hasevaluated a number of potential investments and continues to do so. Costs include fees incurred in respect of a particular transaction which in theevent was aborted during due diligence. For further information: Quintessentially English PLCMr Michael Gurner, 07768 231 731 Profit and Loss AccountFor the period 01/01/05 to 30/06/05 Note Period Ended 30/06/2005 (unaudited) £ Turnover -Administrative expenses (60,633) ------------Operating Loss (60,633)Interest Receivable 4,382Interest Payable (32) ------------Loss on ordinary activities before taxation 1 (56,283)Taxation - ------------Loss on ordinary activities after taxation (56,283) ------------ Basic and diluted earnings per Ordinary share (pence)(0.50) ------------ Dividends per share (pence) 0 ------------ Balance Sheet As at 30/06/05 Note 30/06/2005 (unaudited) £ £ Fixed assets Investments 2 Current AssetsCash at bank and in hand 198,277Current LiabilitiesCreditors: Amounts falling due within one year (48,120) ------------Net current assets 150,157 -----------Total assets less current liabilities 150,159 ----------- Called up share capital 2 111,769Share premium 3 167,867Profit and loss account (129,477) -----------Equity shareholders funds 150,159 -----------Net assets per share (pence) 4 1.34p ----------- Cash Flow Statement For the period from 01/01/05 to 30/06/05 Note Period Ended 30/06/2005 (unaudited) £ Net cash inflow from operating activities (28,677) ----------- Returns on investment and servicing of finance:Interest received 4,382Interest payable (32) -----------Decrease in cash (24,327) ----------- Notes to the Interim Report 1. Loss on ordinary activities before taxation The loss for the period is representative of operational overheads incurred inthe period. 2. Called up share Capital The issued share capital compromises 11,176,865 ordinary shares of 1p each,consisting of 200 shares of 1p each issued as two £1 subscriber shares onincorporation and converted into 1p shares on 23rd February 2004, 6,666,665ordinary shares of 1p each issued on 24th February 2004 and 4,510,000 ordinaryshares of 1p each issued on 18th March 2004. 3. Share premium The share premium represents: £Premium arising on issues of ordinary shares in the period ended 31/12/2004 213,731Expenses of share issues in the period ending 31/12/2004 (45,864) -----------At 30th June 2005 167,867 ----------- 4. Net assets per share The calculation of net assets per share is based on the net assets at the end ofthe period of £150,159 and on the number of ordinary shares in issue(11,176,865) at 30th June 2005. 5. Preparation of Interim Report The interim financial information for the period from 1 January 2005 to 30thJune 2005 was approved by the directors on 19 September 2005. 6. Financial information The financial information in this statement does not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. 7. Availability Copies of the interim financial information for the period from 1 January 2005to 30th June 2005 are not being sent to shareholders. Copies will be availablefrom the Company's registered office, which is at 235 Old Marylebone Road,London NW1 50T. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.